{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T04:23:11Z","timestamp":1779250991260,"version":"3.51.4"},"reference-count":18,"publisher":"MDPI AG","issue":"12","license":[{"start":{"date-parts":[[2022,11,29]],"date-time":"2022-11-29T00:00:00Z","timestamp":1669680000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Current Oncology"],"abstract":"<jats:p>Background: Screening for latent tuberculosis infection (LTBI) in patients with hematological malignancy is recommended because of their increased risk of tuberculosis (TB). We assessed the utility of tuberculin skin test (TST) screening in patients with acute leukemia and subsequent outcomes of LTBI treatment. Methods: We retrospectively evaluated patients \u226516 years of age with acute leukemia from 2013\u20132014 with a TST planted and read prior to the initiation of antineoplastic chemotherapy treatment. Demographics, clinical information and treatment outcomes of LTBI therapy were compared between patients with positive TST (\u226510 mm induration) and negative TST. Results: A total of 389 patients with acute leukemia were included in the cohort. Of them, 37\/389 (9.5%) had a positive TST. Only 3.4% (8\/235) of individuals originating from North and South America as well as the Caribbean were TST positive, while 21% (20\/95) of individuals from Asia were TST positive. Diagnostic imaging findings consistent with prior tuberculosis infection were higher in TST positive patients compared to TST negative ones (29.7% versus 9.4%, p &lt; 0.0001). Furthermore, 31\/38 patients (81.6%) who were TST positive received LTBI therapy, which was well tolerated. There was no significant difference in overall survival among those who received LTBI therapy compared to those who did not. No patients developed active TB. Conclusions: Universal screening with TST may be of low yield in individuals with acute leukemia unless patients originate from a TB endemic country. When therapy for LTBI is prescribed, patients with acute leukemia do not experience drug-induced liver toxicity and are likely to complete the intended duration of therapy, thus preventing the development of active tuberculosis.<\/jats:p>","DOI":"10.3390\/curroncol29120731","type":"journal-article","created":{"date-parts":[[2022,11,30]],"date-time":"2022-11-30T08:46:41Z","timestamp":1669798001000},"page":"9325-9334","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Implementation of a Routine Screening Program for Latent Tuberculosis Infection among Patients with Acute Leukemia at a Canadian Cancer Center"],"prefix":"10.3390","volume":"29","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2596-3079","authenticated-orcid":false,"given":"Rbab","family":"Taha","sequence":"first","affiliation":[{"name":"Immunocompromised Host Infectious Diseases Service, Ajmera Transplant Center, University Health Network, Toronto, ON M5G 2N2, Canada"},{"name":"Department of Medicine, Faculty of Medicine, University of Toronto, Toronto, ON M5S 3H2, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2376-2345","authenticated-orcid":false,"given":"Sagar","family":"Kothari","sequence":"additional","affiliation":[{"name":"Immunocompromised Host Infectious Diseases Service, Ajmera Transplant Center, University Health Network, Toronto, ON M5G 2N2, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Farid","family":"Foroutan","sequence":"additional","affiliation":[{"name":"Ted Rogers Centre for Heart Research, University Health Network, Toronto, ON M5G 2N2, Canada"},{"name":"Department of Health Research Methods, Evidence and Impact, McMaster University, Hamilton, ON L8S 4L8, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6960-0763","authenticated-orcid":false,"given":"Melissa","family":"Gitman","sequence":"additional","affiliation":[{"name":"Department of Pathology, Molecular and Cell-Based Medicine, Icahn School of Medicine at Mount Sinai, Mount Sinai Hospital, New York, NY 10029, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1419-8607","authenticated-orcid":false,"given":"Vikas","family":"Gupta","sequence":"additional","affiliation":[{"name":"Department of Medicine, Faculty of Medicine, University of Toronto, Toronto, ON M5S 3H2, Canada"},{"name":"Division of Medical Oncology, Princess Margaret Cancer Centre, University Health Network, Toronto, ON M5G 2C1, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tram","family":"Nguyen","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology, Princess Margaret Cancer Centre, University Health Network, Toronto, ON M5G 2C1, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1413-0968","authenticated-orcid":false,"given":"Coleman","family":"Rotstein","sequence":"additional","affiliation":[{"name":"Immunocompromised Host Infectious Diseases Service, Ajmera Transplant Center, University Health Network, Toronto, ON M5G 2N2, Canada"},{"name":"Department of Medicine, Faculty of Medicine, University of Toronto, Toronto, ON M5S 3H2, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2022,11,29]]},"reference":[{"key":"ref_1","unstructured":"World Health Organization (2021). Global Tuberculosis Report 2021, World Health Organization."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"68","DOI":"10.14745\/ccdr.v45i23a04","article-title":"Tuberculosis in Canada 2017","volume":"45","author":"LaFreniere","year":"2019","journal-title":"Can. Commun. Dis. Rep."},{"key":"ref_3","first-page":"8","article-title":"Chapter 1: Epidemiology of tuberculosis in Canada","volume":"6","author":"Mounchili","year":"2022","journal-title":"Can. J. Respir. Crit. Care Sleep Med."},{"key":"ref_4","unstructured":"Mounchili, A., Perera, R., Henry, C., Soualhine, H., Sharma, M., Yoshida, C., Rabb, M., and Carew, M. (2022). Tuberculosis Surveillance in Canada 2010\u20132020 Summary Report. Public Health Agency Can., Available online: https:\/\/open.canada.ca\/data\/dataset\/17ee0902-055e-415e-b7aa-d9bee1734d35\/resource\/1a833c68-0daa-440e-a8a2-a2e42d697c4b\/download\/english-pdf-5-english.pdf."},{"key":"ref_5","unstructured":"(2022, May 30). Public Health Ontario. Available online: https:\/\/www.publichealthontario.ca\/data-and-analysis\/commonly-used-products\/reportable-disease-trends-annually#\/2."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1097\/00005382-199701000-00006","article-title":"Tuberculosis in cancer patients: An update","volume":"12","author":"Libshitz","year":"1997","journal-title":"J. Thorac. Imaging"},{"key":"ref_7","first-page":"635","article-title":"Risk of active tuberculosis in patients with cancer: A systematic review and metaanalysis","volume":"64","author":"Cheng","year":"2017","journal-title":"Clin. Infect. Dis."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1007\/s12288-017-0875-z","article-title":"Analysis of clinical profile and outcome of tuberculosis in patients with acute leukemia","volume":"34","author":"Jain","year":"2018","journal-title":"Indian J. Hematol. Blood Transfus."},{"key":"ref_9","unstructured":"Menzies, D., Alvarez, G.G., and Khan, K. (2014). Chapter 6 Treatment of latent tuberculosis. Canadian Tuberculosis Standards, Public Health Agency of Canada. [7th ed.]."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1378\/chest.08-2575","article-title":"Performance of tests for latent tuberculosis in different groups of immunocompromised patients","volume":"136","author":"Richeldi","year":"2009","journal-title":"Chest"},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Lee, H.-J., Lee, D.-G., Choi, S.-M., Park, S.H., Cho, S.Y., Choi, J.K., Kim, S.-H., Choi, J.-H., Yoo, J.-H., and Cho, B.-S. (2017). The demanding attention of tuberculosis in allogeneic hematopoietic stem cell transplantation recipients: High incidence compared with general population. PLoS ONE, 12.","DOI":"10.1371\/journal.pone.0173250"},{"key":"ref_12","first-page":"847","article-title":"How much isoniazid is needed for the prevention of tuberculosis in immunocompetent adults?","volume":"3","author":"Comstock","year":"1999","journal-title":"Int. J. Tuberc. Lung Dis."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"e2014026","DOI":"10.4084\/mjhid.2014.026","article-title":"Tuberculosis in patients with haematological malignancies","volume":"6","author":"Anibarro","year":"2014","journal-title":"Mediterr. J. Hematol. Infect. Dis."},{"key":"ref_14","unstructured":"Pai, M., Kunimoto, D., Jamieson, F., and Menzies, D. (2014). Chapter 4 Diagnosis of latent tuberculosis infection. Canadian Tuberculosis Standards, Public Health Agency of Canada. [7th ed.]."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1164\/ajrccm\/145.3.621","article-title":"Effect of bacille Calmette-Guerin vaccination on tuberculin reactivity","volume":"145","author":"Menzies","year":"1992","journal-title":"Am. Rev. Respir. Dis."},{"key":"ref_16","first-page":"1192","article-title":"False-positive tuberculin skin tests: What is the absolute effect of BCG and non-tuberculous mycobacteria?","volume":"10","author":"Farhat","year":"2006","journal-title":"Int. J. Tuberc. Lung Dis."},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Osorio-Lopez, E.A., Vilar-Compte, D., Garcia-Tirado, J., and Martin-Onraet, A. (2021). Prevalence of latent tuberculosis in patients with hematological neoplasmsin a cancer referral hospital in Mexico City. BMC Infect. Dis., 21.","DOI":"10.1186\/s12879-021-06236-y"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1007\/s15010-013-0489-9","article-title":"Toxicity and adherence to treatment for latent tuberculosis infection in patients with hematologic malignancies","volume":"41","author":"Gamalho","year":"2013","journal-title":"Infection"}],"container-title":["Current Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1718-7729\/29\/12\/731\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T01:29:04Z","timestamp":1760146144000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1718-7729\/29\/12\/731"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,29]]},"references-count":18,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["curroncol29120731"],"URL":"https:\/\/doi.org\/10.3390\/curroncol29120731","relation":{},"ISSN":["1718-7729"],"issn-type":[{"value":"1718-7729","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,29]]}}}